Clinical trial
Phase 2 Crossover Study Assessing the Effect of Moderate Alcohol Intake on the Absorption and Onset of Action of Hezkue® Sildenafil Oral Suspension
NCT07290400 is registered in ClinicalTrials.gov with Aspargo Labs, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Crossover Study Assessing the Effect of Moderate Alcohol Intake on the Absorption and Onset of Action of Hezkue® Sildenafil Oral Suspension
- Lead sponsor
- Aspargo Labs, Inc
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- April 15, 2026
- Completion date
- June 28, 2026
- Enrollment
- 36 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.